Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 2/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL350280 | 1.00 | TP53 (0.48) | TP53TSHRKDM4ETDP1KMT2A | |
| SCHEMBL350279 | 1.00 | TP53 (0.48) | TP53TSHRKDM4ETDP1KMT2A | |
| SCHEMBL4195533 | 0.86 | KMT2A (0.59) | TDP1KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL4195531 | 0.86 | KMT2A (0.59) | TDP1KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL1485846 | 0.85 | LMNA (0.43) | TSHRKDM4ETDP1KMT2AMEN1 | |
| SCHEMBL27999259 | 0.85 | POLB (0.48) | TSHRTDP1KMT2AMEN1LMNA | |
| SCHEMBL1663456 | 0.83 | HCAR3 (0.55) | TP53TSHRKDM4ETDP1KMT2A | |
| SCHEMBL669563 | 0.83 | MAPK13 (0.61) | KDM4EKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL669564 | 0.83 | MAPK13 (0.61) | KDM4EKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL7146207 | 0.82 | F2 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193285-A1 | Neuroprotectants formulations and methods | NEURON THERAPEUTICS | 2002-12-19 | — | — | US | claimed |
| US-8992949-B1 | Biocompatible polymeric compositions having microcrystalline and amorphous components and methods for their manufacture | UNICARE BIOMEDICAL, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| EP-1539169-A2 | AMYOTROPHIC LATERAL SCLEROSIS TREATMENT WITH CYCLOOXYGENASE-2 INHIBITORS | Pharmacia Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040063751-A1 | Combination therapy for the treatment of amyotrophic lateral sclerosis (ALS) with cyclooxygenase-2 (COX-2) inhibitor(s) and a second drug | PHARMACIA CORPORATION | 2004-04-01 | — | — | US | disclosed |
| WO-2003101380-A2 | AMYOTROPHIC LATERAL SCLEROSIS TREATMENT WITH CYCLOOXYGENASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| EP-0776364-A1 | GLUTAMATE RECEPTOR | Novartis AG (CH) | 1997-06-04 | — | — | EP | disclosed |
| WO-1996006167-A1 | GLUTAMATE RECEPTOR | NOVARTIS AG (CH) | 1996-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063751-A1 | Combination therapy for the treatment of amyotrophic lateral sclerosis (ALS) with cyclooxygenase-2 (COX-2) inhibitor(s) and a second drug | SMN1; SMN2, PTGS2, PTGES2 | TP53 4055/4885TSHR 4695/4885KDM4E 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.